News Releases

November 18, 2020
Synlogic to Present at Upcoming Virtual Banking Conference
CAMBRIDGE, Mass. , Nov. 18, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
November 5, 2020
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update
- Synlogic ends 3Q2020 with $102.0 million in cash, cash equivalents and investments supporting projected runway into 2022 -   - Phase 2 study of SYNB1618 and Phase 1 study of SYNB8802 initiated -   - Management to host conference call and webcast at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Nov....
November 4, 2020
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria
CAMBRIDGE, Mass. , Nov. 4, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced it has treated the first healthy volunteer in its Phase 1 study of the investigational Synthetic Biotic...
October 27, 2020
Synlogic Announces Third Quarter 2020 Conference Call & Webcast
CAMBRIDGE, Mass. , Oct. 27, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday,...
October 22, 2020
Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020
CAMBRIDGE, Mass. , Oct. 22, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present a poster on SYNB8802, an investigational Synthetic Biotic medicine for the treatment...
September 14, 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass. , Sept. 14, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of David Hava , Ph.D. as Chief Scientific Officer. Dr....
September 8, 2020
Synlogic to Present at Upcoming Virtual Banking Conferences
CAMBRIDGE, Mass. , Sept. 8, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...
August 6, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update
- Synlogic ends 2Q2020 with $109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 - Company continues to advance multiple clinical stage Synthetic Biotic medicines - Management to host conference call and webcast at 8:00 am ET today - CAMBRIDGE,...
July 31, 2020
Synlogic to Present at Upcoming Virtual Banking Conferences
CAMBRIDGE, Mass. , July 31, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's president and chief executive officer, and other members of...
July 30, 2020
Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team
CAMBRIDGE, Mass. , July 30, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Antoine 'Tony' Awad to the position of Chief Operating Officer....
July 28, 2020
Synlogic Announces Second Quarter 2020 Conference Call & Webcast
CAMBRIDGE, Mass. , July 28, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2020 financial results before the market opens on Thursday,...
June 1, 2020
Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors
- SYNB1891 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma - CAMBRIDGE, Mass. , June 1, 2020 /PRNewswire/ --  Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel,...
Displaying 1 - 12 of 120